21 Dec 2018 16:29
21 December 2018
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Director/PDMR Dealings
Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces that Michael Ryan, Senior Independent Director, has sold 138,672 ordinary shares in Venn at a price of 1.9p per share, in order to crystalise certain capital tax losses. Following this sale, Mr Ryan remains interested in 134,586 ordinary shares in the Company.
Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Michael Ryan
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Senior Independent Director | |||
b)
| Initial notification /Amendment | Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
b) | Name
LEI code | Venn Life Science Holdings PLC
213800VT5KBM7JLIV118 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of nominal value of 0.1 pence each | |||
Identification code | ISIN GB00B9275X97 | ||||
b)
| Nature of the transaction
| Sale of ordinary shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1.9p per share | 138,672 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | N/A - single transaction | ||||
- Price | |||||
e)
| Date of the transaction
| 21 December 2018 | |||
f)
| Place of the transaction
| London Stock Exchange (AIM) | |||
Enquiries:
Venn Life Sciences Holdings Plc | ||
Tony Richardson, Chief Executive Officer | Tel: +353 1 5499341 | |
Cenkos (Nominated Advisor and Co-Broker) Mark Connelly/Steve Cox (Corporate Finance) | Tel: +44(0)20 7397 8900 | |
Davy (ESM Adviser and Co-Broker) | ||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | |
About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.vennlifesciences.com